辛伐他汀联合低分子肝素对慢性心衰心肺功能及相关指标的影响

目的:探索辛伐他汀联合低分子肝素对慢性心力衰竭(CHF)患者的D-二聚体、N-末端脑钠肽前体(NT-proBNP)、左室射血分数(LVEF)、左室舒末内径、血清反应蛋白(CRP)、血浆纤维蛋白原(FB)、血清总胆固醇(TC)及低密度脂蛋白胆固醇(LDL-C)的影响。方法:选择我院自2010年4月至2014年7月间收治的患有CHF患者80例,按照随机数表法分成治疗组和对照组,各40例。两组均给予常规治疗,治疗组在常规治疗的基础上加用辛伐他汀和低分子肝素,治疗两个月。对比两组患者治疗前后D-二聚体、NT-proBNP、LVEF、左室舒末内径、CRP、FB、TC和LDL-C水平。结果:与治疗前相比,对照组患者治疗后的D-二聚体、NT-proBNP、LVEF、左室舒末内径、CRP、FB、TC和LDL-C水平均无明显改善,而治疗组患者上述各项指标均显著改善,差异均具有统计学意义(均P0.05)。结论:临床上应用辛伐他汀联合低分子肝素可以有效改善CHF患者的相关指标,对于疾病的治疗具有重要作用,值得在临床上应用及推广。

Influence of Simvastatin plus Low Molecular Heparin on CardiopulmonaryFunction and Relevant Indexes in Chronic Heart Failure

Objective:To explore the influence of simvastatin plus low molecular heparin on D-dimer, N-terminal brain natriureticpeptide precursor(NT-proBNP), left ventricular ejection fraction(LVEF), left ventricular end-diastolic diameter, serum c-reactive protein(CRP), plasma fibrinogen (FB), serumtotal cholesterol (TC), low density lipoprotein cholesterol (LDL-C) in patients with chronic heartfailure (CHF).Methods:A total of 80 patients with CHF, who were treated in Dalian Center Hospital fromApril 2010 to July 2014 ,wereselected and randomly divided into treatment group (n=40) and control group (n=40). The two groups were all treated with conventionaltherapy, based on which, the treatment group was added simvastatin plus low molecular heparin, the course of treatment was two months.The levels of D-dimer, NT-proBNP, LVEF, left ventricular end-diastolic diameter, CRP, FB, TC and LDL-C in the two groups before andafter treatment were compared.Results:Compared with before treatment, the levels of D-dimer, NT-proBNP, LVEF, left ventricularend-diastolic diameter, CRP, FB, TC and LDL-C in the control group after treatment were not obviously improved, while the aboveindexes in the treatment group were improved significantly, the differences were statistically significant(P<0.05).Conclusion:Simvastatinplus low molecular heparin can effectively improve the relevant indexe of patients with CHF, which plays an important role in the clinicaltreatment and is worthy of clinical application.